Literature DB >> 17359592

Controlled natural cycle IVF: experience in a world of stimulation.

Simon J Phillips1, Isaac Jacques Kadoch, Louise Lapensée, Bernard Couturier, Robert Hemmings, François Bissonnette.   

Abstract

A total of 134 controlled natural IVF (nIVF) cycles were reviewed retrospectively and compared with 370 stimulated IVF (sIVF) cycles. The clinical pregnancy rate per embryo transfer following nIVF was 27% and 47% in sIVF cycles for patients aged less than 35. However, natural cycle patients could attempt consecutive cycles with much less impact on their lives, both medically and financially. In patients under 35 years of age, the choice of controlled nIVF reduces the cost and risk to the patient, permitting her to have multiple, consecutive attempts, and cumulatively offers a clinical pregnancy rate which approaches that of sIVF. The multiple pregnancy rate in nIVF is significantly reduced compared with sIVF treatment cycles. In patients over 35 years of age the benefits of nIVF were much less evident (clinical pregnancy rate: 8% per embryo transfer) and the opportunity to transfer multiple embryos in these patients seems to be advantageous.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17359592     DOI: 10.1016/s1472-6483(10)60879-6

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  2 in total

1.  Outcomes of 1503 cycles of modified natural cycle in vitro fertilization: a single-institution experience.

Authors:  Talya Shaulov; Maria P Vélez; Karen Buzaglo; Simon J Phillips; Isaac Jacques Kadoch
Journal:  J Assist Reprod Genet       Date:  2015-06-04       Impact factor: 3.412

2.  Prediction of Fertilization Disorders in the In Vitro Fertilization/Intracytoplasmic Sperm Injection: A Retrospective Study of 106,728 Treatment Cycles.

Authors:  Tian Tian; Lixue Chen; Rui Yang; Xiaoyu Long; Qin Li; Yongxiu Hao; Fei Kong; Rong Li; Yuanyuan Wang; Jie Qiao
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-20       Impact factor: 6.055

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.